Logo

Biomedicine & Healthcare Research

Logo
Back to Articles

Concurrent gastrointestinal stromal tumor and small bowel adenocarcinoma in neurofibromatosis type 1: A rare case report

Submission Type:Original Research Article

1 Pathological Anatomy and Cytology Department of Sahloul University Hospital, Sousse,

2 Pathological Anatomy and Cytology Department of Sahloul University Hospital, Sousse,

Abstract

Introduction: Nasopharyngeal cancer is a distinctive entity compared to other head and neck cancers. In Tunisia, it is ranked as the second most common head and neck cancer after laryngeal cancer. Although its pathophysiology is unclear, several genetic and infectious predisposing factors have been identified. However, there is limited data available on environmental and occupational factors.

Material and method: This is a retrospective descriptive survey of the records of subjects with nasopharyngeal cancer. These subjects consulted the occupational medicine department of the Farhat Hached University Hospital, Sousse, over a 10-year period from 1 January 2010 to 31 December 2019.

Results: A total of four cases were recorded, illustrating a variety of occupational exposures. All patients were males. Cervical adenopathy was the first symptom to appear. The diagnosis was confirmed by biopsy. Pathological examination revealed 3 undifferentiated nasopharyngeal carcinoma (UCNT) and one well-differentiated non-keratinizing squamous cell carcinoma. Two patients were welders; one was a qualified dairy production operator and the fourth was a worker in a car company. Three patients were exposed to formaldehyde and one to wood dust with an average seniority of 11.25 years. All four cases had their cancer recognized as an occupational disease according to table 28 or 54.

Conclusion: All cases of nasopharyngeal cancer should be considered work-related, to ensure recognition as an occupational disease and to safeguard patients' rights to treatment and compensation.

Main Subjects

Pharma

Keywords

Neurofibromatosis Type 1
GIST
Adenocarcinoma
Small intestine

License

Journal License

This work is licensed under a Creative Commons Attribution 4.0 International license

issue-coversheet

V5, 1

Files

PDF

Article Insights

Article Views

1

PDF Downloads

0

References

  1. Tamura R. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. Int J Mol Sci. 2021;22(11):5850. https://doi.org/10.3390/ijms22115850

  2. Nix JS, Blakeley J, Rodriguez FJ. An update on the central nervous system manifestations of neurofibromatosis type 1. Acta Neuropathol. 2020;139(4):625–41. https://doi.org/10.1007/s00401-019-02002-2

  3. Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S. An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol. 2020;139(4):643–65. https://doi.org/10.1007/s00401-019-02029-5

  4. Lee JM, Lee JM, Hyun JJ, Choi HS, Kim ES, Keum B, et al. Intraductal papillary bile duct adenocarcinoma and gastrointestinal stromal tumor in a case of neurofibromatosis type 1. World J Gastroenterol. 2018;24(4):537–42. https://doi.org/10.3748/wjg.v24.i4.537

  5. Zhang W, Hu X, Chen Z, Lai C. Case report: Neurofibromatosis type 1 gastrointestinal stromal tumor and small bowel adenocarcinoma with a novel germline NF1 frameshift mutation. Front Oncol. 2022;12:1052799. https://doi.org/10.3389/fonc.2022.1052799

  6. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol. 2007;6(4):340–51. https://doi.org/10.1016/S1474-4422(07)70075-3

  7. Kistler CA, Johnson JM, Winter JM, Baliff JP, Siddiqui AA, Sama AR. A case of periampullary adenocarcinoma in neurofibromatosis type 1. J Gastrointest Oncol. 2014;5(6):E96–9. https://doi.org/10.3978/j.issn.2078-6891.2014.047

  8. Relles D, Baek J, Witkiewicz A, Yeo CJ. Periampullary and duodenal neoplasms in neurofibromatosis type 1. J Gastrointest Surg. 2010;14(6):1052–61. https://doi.org/10.1007/s11605-009-1123-0

  9. Raghav K, Overman MJ. Small bowel adenocarcinomas—existing evidence and evolving paradigms. Nat Rev Clin Oncol. 2013;10(9):534–44. https://doi.org/10.1038/nrclinonc.2013.132

  10. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(9):1109–33. https://doi.org/10.6004/jnccn.2019.0043

  11. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States. Ann Surg. 2009;249(1):63–71. https://doi.org/10.1097/SLA.0b013e31818e4641

  12. Lowenfels AB. Why are small-bowel tumours so rare? Lancet. 1973;1(7793):24–6.

  13. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel. Cancer. 2004;101(3):518–26. https://doi.org/10.1002/cncr.20404

  14. Negoi I, Paun S, Hostiuc S, Stoica B, Tanase I, Negoi RI, Beuran M. Most small bowel cancers are revealed by a complication. Einstein (Sao Paulo). 2015;13(4):500–5. https://doi.org/10.1590/S1679-45082015AO3380

  15. Gustafsson BI, Siddique L, Chan A, Dong M, Drozdov I, Kidd M, Modlin IM. Uncommon cancers of the small intestine. Int J Oncol. 2008;33(6):1121–31.

  16. Uusitalo E, Rantanen M, Kallionpää RA, Pöyhönen M, Leppävirta J, Ylä-Outinen H, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34(17):1978–86. https://doi.org/10.1200/JCO.2015.65.3576

  17. Scheffzek K, Ahmadian MR, Wiesmüller L, Kabsch W, Stege P, Schmitz F, Wittinghofer A. Structural analysis of the GAP-related domain from neurofibromin. EMBO J. 1998;17(15):4313–27. https://doi.org/10.1093/emboj/17.15.4313

  18. Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I, Baralle D. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer. 2006;95(2):233–8. https://doi.org/10.1038/sj.bjc.6603227

  19. Zöller ME, Rembeck B, Odén A, Samuelsson M, Angervall L. Tumors in patients with neurofibromatosis type 1. Cancer. 1997;79(11):2125–31.

  20. Dupuis H, Chevalier B, Cardot-Bauters C, Jannin A, Cao CD, Ladsous M, et al. Endocrine manifestations and GIST in NF1. J Endocr Soc. 2023;7(8):bvad083. https://doi.org/10.1210/jendso/bvad083

  21. Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006;17(Suppl 10):x280–6. https://doi.org/10.1093/annonc/mdl274

  22. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in GISTs. Science. 2003;299(5607):708–10. https://doi.org/10.1126/science.1079666

  23. Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P. Therapeutic consequences for GIST patients with NF1. Clin Cancer Res. 2008;14(14):4550–5. https://doi.org/10.1158/1078-0432.CCR-08-0086

  24. Maruta H, Burgess AW. Regulation of the Ras signalling network. Bioessays. 1994;16(7):489–96.

  25. Latham A, Shia J, Patel Z, Reidy-Lagunes DL, Segal NH, Yaeger R, et al. DNA mismatch repair–deficient small bowel adenocarcinoma. Clin Cancer Res. 2021;27(5):1429–37. https://doi.org/10.1158/1078-0432.CCR-20-2892

  26. Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, et al. Microsatellite instability and Lynch syndrome. J Clin Oncol. 2019;37(4):286–95. https://doi.org/10.1200/JCO.18.00283

  27. Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, et al. Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol. 2017;3(11):1546–53. https://doi.org/10.1001/jamaoncol.2017.1051

  28. Hampel H, Frankel WL, Martin E, et al. Screening for Lynch syndrome. N Engl J Med. 2005;352(18):1851–60. https://doi.org/10.1056/NEJMoa043146